Search Results
Gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed FLT3-mutated AML
Patient-reported outcomes in FLT3-mutated AML patients treated with gilteritinib plus azacitidine
Phase III trial of azacitidine and gilteritinib in FLT3 mutant AML
FLT3 mutation clearance rate in patients with newly diagnosed AML
Updates from the Phase III LACEWING trial
Crenolanib plus 7+3 chemotherapy in adults with newly diagnosed FLT3-mutated AML.
Venetoclax plus azacitidine in FLT3-mutated AML
Gilteritinib plus venetoclax for R/R FLT3-mutated AML
Moving to the frontline: gilteritinib plus chemo for newly diagnosed AML
The use of doublets vs triplets for FLT3-mutated AML
AML data at ASH 2021 and implications on clinical practice
Clinical trials investigating treatment approaches for FLT3-mutated and IDH-mutated AML patients
